Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve diseasePRNewsWire • Thursday
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks24/7 Wall Street • Tuesday
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?Zacks Investment Research • Tuesday
Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds AheadSeeking Alpha • Tuesday
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPRNewsWire • Monday
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?The Motley Fool • 10/24/26
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancerPRNewsWire • 10/23/26
Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and OutlookZacks Investment Research • 10/22/26
Abbott Q3: Nutrition Spin-Out, Narrowed Guidance Rocks Stock; For Now, At LeastSeeking Alpha • 10/21/26
ABT Stock Down Post Q3 Earnings Miss, Revenues Rise Y/Y, Margins UpZacks Investment Research • 10/21/26
Abbott (ABT) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 10/21/26